世界の腫瘍壊死因子受容体スーパーファミリーメンバー9市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-6055 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、腫瘍壊死因子受容体スーパーファミリーメンバー9の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（Ultra-41BBL、PRS-342、ISAS-01、EU-101、その他）、用途別市場規模（胃がん、膀胱がん、子宮頸がん、リンパ腫、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・腫瘍壊死因子受容体スーパーファミリーメンバー9の市場動向 ・企業の競争状況、市場シェア ・腫瘍壊死因子受容体スーパーファミリーメンバー9の種類別市場規模と予測2016-2027（Ultra-41BBL、PRS-342、ISAS-01、EU-101、その他） ・腫瘍壊死因子受容体スーパーファミリーメンバー9の用途別市場規模と予測2016-2027（胃がん、膀胱がん、子宮頸がん、リンパ腫、その他） ・腫瘍壊死因子受容体スーパーファミリーメンバー9の北米市場規模2016-2027（アメリカ、カナダ） ・腫瘍壊死因子受容体スーパーファミリーメンバー9の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・腫瘍壊死因子受容体スーパーファミリーメンバー9のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・腫瘍壊死因子受容体スーパーファミリーメンバー9の中南米市場規模2016-2027（メキシコ、ブラジル） ・腫瘍壊死因子受容体スーパーファミリーメンバー9の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（Agenus Inc、Alligator Bioscience AB、Apogenix GmbH、BioInvent International AB、Eli Lilly and Co、Juno Therapeutics Inc、MacroGenics Inc、Pfizer Inc、Pieris Pharmaceuticals Inc） ・結論

Market Analysis and Insights: Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market
The global Tumor Necrosis Factor Receptor Superfamily Member 9 market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Tumor Necrosis Factor Receptor Superfamily Member 9 market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Tumor Necrosis Factor Receptor Superfamily Member 9 market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Tumor Necrosis Factor Receptor Superfamily Member 9 market.

Global Tumor Necrosis Factor Receptor Superfamily Member 9 Scope and Market Size
Tumor Necrosis Factor Receptor Superfamily Member 9 market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Tumor Necrosis Factor Receptor Superfamily Member 9 market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Ultra-41BBL
PRS-342
ISAS-01
EU-101
Others

Segment by Application
Gastric Cancer
Bladder Cancer
Cervical Cancer
Lymphoma
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Agenus Inc
Alligator Bioscience AB
Apogenix GmbH
BioInvent International AB
Eli Lilly and Co
Juno Therapeutics Inc
MacroGenics Inc
Pfizer Inc
Pieris Pharmaceuticals Inc

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Ultra-41BBL
1.2.3 PRS-342
1.2.4 ISAS-01
1.2.5 EU-101
1.2.6 Others
1.3 Market by Application
1.3.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Gastric Cancer
1.3.3 Bladder Cancer
1.3.4 Cervical Cancer
1.3.5 Lymphoma
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Perspective (2016-2027)
2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Growth Trends by Regions
2.2.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Share by Regions (2016-2021)
2.2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Regions (2022-2027)
2.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Industry Dynamic
2.3.1 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Trends
2.3.2 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Drivers
2.3.3 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Challenges
2.3.4 Tumor Necrosis Factor Receptor Superfamily Member 9 Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue
3.1.1 Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Revenue (2016-2021)
3.1.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Players (2016-2021)
3.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue
3.4 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Concentration Ratio
3.4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue in 2020
3.5 Tumor Necrosis Factor Receptor Superfamily Member 9 Key Players Head office and Area Served
3.6 Key Players Tumor Necrosis Factor Receptor Superfamily Member 9 Product Solution and Service
3.7 Date of Enter into Tumor Necrosis Factor Receptor Superfamily Member 9 Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Type
4.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Type (2016-2021)
4.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Type (2022-2027)

5 Tumor Necrosis Factor Receptor Superfamily Member 9 Breakdown Data by Application
5.1 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Historic Market Size by Application (2016-2021)
5.2 Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2016-2027)
6.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
6.2.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021)
6.2.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027)
6.2.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2027)
6.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
6.3.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021)
6.3.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027)
6.3.3 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2027)
6.4 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
6.4.1 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021)
6.4.2 North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2016-2027)
7.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
7.2.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021)
7.2.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027)
7.2.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2027)
7.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
7.3.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021)
7.3.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027)
7.3.3 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2027)
7.4 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
7.4.1 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021)
7.4.2 Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2016-2027)
8.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
8.2.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2027)
8.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
8.3.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2027)
8.4 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region
8.4.1 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2016-2027)
9.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
9.2.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021)
9.2.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027)
9.2.3 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2027)
9.3 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
9.3.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021)
9.3.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027)
9.3.3 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2027)
9.4 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
9.4.1 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021)
9.4.2 Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (2016-2027)
10.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type
10.2.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2027)
10.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application
10.3.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2027)
10.4 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country
10.4.1 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 Agenus Inc
11.1.1 Agenus Inc Company Details
11.1.2 Agenus Inc Business Overview
11.1.3 Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.1.4 Agenus Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.1.5 Agenus Inc Recent Development
11.2 Alligator Bioscience AB
11.2.1 Alligator Bioscience AB Company Details
11.2.2 Alligator Bioscience AB Business Overview
11.2.3 Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.2.4 Alligator Bioscience AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.2.5 Alligator Bioscience AB Recent Development
11.3 Apogenix GmbH
11.3.1 Apogenix GmbH Company Details
11.3.2 Apogenix GmbH Business Overview
11.3.3 Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.3.4 Apogenix GmbH Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.3.5 Apogenix GmbH Recent Development
11.4 BioInvent International AB
11.4.1 BioInvent International AB Company Details
11.4.2 BioInvent International AB Business Overview
11.4.3 BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.4.4 BioInvent International AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.4.5 BioInvent International AB Recent Development
11.5 Eli Lilly and Co
11.5.1 Eli Lilly and Co Company Details
11.5.2 Eli Lilly and Co Business Overview
11.5.3 Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.5.4 Eli Lilly and Co Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.5.5 Eli Lilly and Co Recent Development
11.6 Juno Therapeutics Inc
11.6.1 Juno Therapeutics Inc Company Details
11.6.2 Juno Therapeutics Inc Business Overview
11.6.3 Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.6.4 Juno Therapeutics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.6.5 Juno Therapeutics Inc Recent Development
11.7 MacroGenics Inc
11.7.1 MacroGenics Inc Company Details
11.7.2 MacroGenics Inc Business Overview
11.7.3 MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.7.4 MacroGenics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.7.5 MacroGenics Inc Recent Development
11.8 Pfizer Inc
11.8.1 Pfizer Inc Company Details
11.8.2 Pfizer Inc Business Overview
11.8.3 Pfizer Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.8.4 Pfizer Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.8.5 Pfizer Inc Recent Development
11.9 Pieris Pharmaceuticals Inc
11.9.1 Pieris Pharmaceuticals Inc Company Details
11.9.2 Pieris Pharmaceuticals Inc Business Overview
11.9.3 Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Introduction
11.9.4 Pieris Pharmaceuticals Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
11.9.5 Pieris Pharmaceuticals Inc Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Ultra-41BBL
Table 3. Key Players of PRS-342
Table 4. Key Players of ISAS-01
Table 5. Key Players of EU-101
Table 6. Key Players of Others
Table 7. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Regions (2016-2021)
Table 11. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Regions (2022-2027)
Table 13. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Trends
Table 14. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Drivers
Table 15. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Challenges
Table 16. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Restraints
Table 17. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Players (2016-2021)
Table 19. Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 as of 2020)
Table 20. Ranking of Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Tumor Necrosis Factor Receptor Superfamily Member 9 Product Solution and Service
Table 24. Date of Enter into Tumor Necrosis Factor Receptor Superfamily Member 9 Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2016-2021)
Table 28. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2016-2021)
Table 32. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size by Country (2022-2027) & (US$ Million)
Table 64. Agenus Inc Company Details
Table 65. Agenus Inc Business Overview
Table 66. Agenus Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 67. Agenus Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 68. Agenus Inc Recent Development
Table 69. Alligator Bioscience AB Company Details
Table 70. Alligator Bioscience AB Business Overview
Table 71. Alligator Bioscience AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 72. Alligator Bioscience AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 73. Alligator Bioscience AB Recent Development
Table 74. Apogenix GmbH Company Details
Table 75. Apogenix GmbH Business Overview
Table 76. Apogenix GmbH Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 77. Apogenix GmbH Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 78. Apogenix GmbH Recent Development
Table 79. BioInvent International AB Company Details
Table 80. BioInvent International AB Business Overview
Table 81. BioInvent International AB Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 82. BioInvent International AB Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 83. BioInvent International AB Recent Development
Table 84. Eli Lilly and Co Company Details
Table 85. Eli Lilly and Co Business Overview
Table 86. Eli Lilly and Co Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 87. Eli Lilly and Co Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 88. Eli Lilly and Co Recent Development
Table 89. Juno Therapeutics Inc Company Details
Table 90. Juno Therapeutics Inc Business Overview
Table 91. Juno Therapeutics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 92. Juno Therapeutics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 93. Juno Therapeutics Inc Recent Development
Table 94. MacroGenics Inc Company Details
Table 95. MacroGenics Inc Business Overview
Table 96. MacroGenics Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 97. MacroGenics Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 98. MacroGenics Inc Recent Development
Table 99. Pfizer Inc Company Details
Table 100. Pfizer Inc Business Overview
Table 101. Pfizer Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 102. Pfizer Inc Recent Development
Table 103. Pieris Pharmaceuticals Inc Company Details
Table 104. Pieris Pharmaceuticals Inc Business Overview
Table 105. Pieris Pharmaceuticals Inc Tumor Necrosis Factor Receptor Superfamily Member 9 Product
Table 106. Pieris Pharmaceuticals Inc Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021) & (US$ Million)
Table 107. Pieris Pharmaceuticals Inc Recent Development
Table 108. Research Programs/Design for This Report
Table 109. Key Data Information from Secondary Sources
Table 110. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type: 2020 VS 2027
Figure 2. Ultra-41BBL Features
Figure 3. PRS-342 Features
Figure 4. ISAS-01 Features
Figure 5. EU-101 Features
Figure 6. Others Features
Figure 7. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application: 2020 VS 2027
Figure 8. Gastric Cancer Case Studies
Figure 9. Bladder Cancer Case Studies
Figure 10. Cervical Cancer Case Studies
Figure 11. Lymphoma Case Studies
Figure 12. Others Case Studies
Figure 13. Tumor Necrosis Factor Receptor Superfamily Member 9 Report Years Considered
Figure 14. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 15. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 16. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Regions: 2020 VS 2027
Figure 17. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Regions (2022-2027)
Figure 18. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Players in 2020
Figure 19. Global Top Tumor Necrosis Factor Receptor Superfamily Member 9 Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Tumor Necrosis Factor Receptor Superfamily Member 9 as of 2020
Figure 20. The Top 10 and 5 Players Market Share by Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue in 2020
Figure 21. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2016-2021)
Figure 22. Global Tumor Necrosis Factor Receptor Superfamily Member 9 Revenue Market Share by Type (2022-2027)
Figure 23. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 24. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2016-2027)
Figure 25. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2016-2027)
Figure 26. North America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2016-2027)
Figure 27. United States Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Canada Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 29. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 30. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2016-2027)
Figure 31. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2016-2027)
Figure 32. Europe Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2016-2027)
Figure 33. Germany Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. France Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. U.K. Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Italy Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Russia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Nordic Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 39. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 40. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2016-2027)
Figure 41. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2016-2027)
Figure 42. Asia-Pacific Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Region (2016-2027)
Figure 43. China Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Japan Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. South Korea Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Southeast Asia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. India Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Australia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 49. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 50. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2016-2027)
Figure 51. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2016-2027)
Figure 52. Latin America Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2016-2027)
Figure 53. Mexico Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Brazil Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 55. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 56. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Type (2016-2027)
Figure 57. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Application (2016-2027)
Figure 58. Middle East & Africa Tumor Necrosis Factor Receptor Superfamily Member 9 Market Share by Country (2016-2027)
Figure 59. Turkey Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. Saudi Arabia Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 61. UAE Tumor Necrosis Factor Receptor Superfamily Member 9 Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 62. Agenus Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 63. Alligator Bioscience AB Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 64. Apogenix GmbH Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 65. BioInvent International AB Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 66. Eli Lilly and Co Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 67. Juno Therapeutics Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 68. MacroGenics Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 69. Pfizer Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 70. Pieris Pharmaceuticals Inc Revenue Growth Rate in Tumor Necrosis Factor Receptor Superfamily Member 9 Business (2016-2021)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

---